相关实验视频

Updated: Sep 12, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

在西班牙的RCC中,第一线和后续线的治疗模式. 一个现实世界的描述性横截面研究

José A Arranz¹, Cristina Martínez², Lucía Gallego³

¹Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Future oncology (London, England)

|August 7, 2025

概括

在西班牙,晚期细胞癌 (RCC) 的治疗模式显示,较新的基于免疫的治疗方法的吸收率低于预期. 这项研究强调了转移性RCC (mRCC) 患者的临床建议和现实世界的采用之间的差距.

科学领域:

在瘤学瘤学.
医学实践医学实践
临床研究临床研究

背景情况:

历史上,晚期细胞癌 (RCC) 的治疗选择有限,预后不佳.
氨酸激酶抑制剂 (TKIs) 改善了无进展生存率 (PFS),并允许预后亚组识别 (有利,中等,差).
目前的护理标准涉及免疫检查点抑制剂 (IO) 与TKI或其他IO结合,用于中期/预后不佳的患者,改善整体存活率 (OS).

研究的目的:

评估西班牙转移性RCC (mRCC) 的当前治疗模式.
评估在临床实践中采用较新的组合疗法 (IO/TKI,IO/IO).
为了比较现实世界的治疗数据与既定的临床建议.

主要方法:

通过使用瘤学动态TM数据库进行了横截面观察性研究.
分析了1587名转移性RCC患者的数据,重点关注900名一线清细胞mRCC (mccRCC) 患者.
检查了2022年和2023年的治疗模式,按预后子组分层 (有利,中等,差).

主要成果:

在2022年,在预后良好的mccRCC患者中,92.7%接受了TKI. 对于中期/预后不佳的患者,56.7%接受了TKI,27.5%接受了抗PD1-抗CTLA4,13.8%接受了抗PD1-TKI.
在2023年,具有良好的预后的患者仍然主要接受了TKIs (94.4%). 中期/预后不佳的患者接受了TKI (48.4%),抗PD1-抗CTLA4 (38.3%) 和抗PD1-TKI (12.1%).
总体而言,西班牙IO/IO和IO/TKI组合的使用量低于根据当前指南预期的.

结论:

在西班牙临床实践中,针对先进的RCC采用基于免疫的组合疗法 (IO/IO,IO/TKI) 落后于推.
这表明在实施针对mRCC的新型治疗策略方面存在潜在的障碍或延迟.
进一步调查这种吸收率较低的原因是有必要的,以确保最佳的患者护理.

关键词:

在瘤学瘤学.晚期细胞癌是晚期细胞癌临床实践中的临床实践免疫疗法免疫疗法这就是尼沃卢马布 (nivolumab).瘤学的动态癌症的动态现实世界的证据.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...